|Research Article:||Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy|
|Author:||Weerachai Chaijamorna, Dhakrit Rungkitwattanakul, Sutthiporn Pattharachayakul, Wanchana Singhan, Taniya Charoensareerat, Nattachai Srisawat|
|Department/Faculty||Faculty of Pharmacy, Siam University, Bangkok 10160|
|Published/แหล่งเผยแพร่||Journal of Critical Care Volume 60, December 2020, Pages 285-289|
Weerachai Chaijamorna, Dhakrit Rungkitwattanakul, Sutthiporn Pattharachayakul, Wanchana Singhan, Taniya Charoensareerat & Nattachai Srisawat. (2020). Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. Journal of Critical Care, 60, 285-289. Retrieve from: https://doi.org/10.1016/j.jcrc.2020.09.001
To gather available meropenem pharmacokinetics and define drug dosing regimens for Asian critically ill patients receiving CRRT.
All necessary pharmacokinetic and pharmacodynamic data from Asian population were gathered to develop mathematic models with first-order elimination. Meropenem concentration-time profiles were calculated to evaluate efficacy based on the probability of target attainment (PTA) of 40%fT>4MIC. A group of 5000 virtual patients was created and tested using Monte Carlo simulations for each dose in the models. The optimal dosing regimens were defined as the doses achieved at least 90% of the PTA.
The recommended meropenem dosing regimen for Asian critically ill patients receiving CRRT with standard (20–25 mL/kg/h) and high (35 mL/kg/h) effluent rates was 750 mg q 8 h to manage Gram-negative infections with expected MIC < 2 mg/L in virtual Asian patients. Some meropenem dosages from available clinical resources could not achieve the aforementioned target. The volume of distribution, body weights and nonrenal clearance significantly contributed to drug dosing adaptation, especially in the specific population.
A meropenem regimen of 750 mg q 8 h was recommended for Asian critically ill patients receiving 2 different CRRT modalities with standard and high effluent rates. Clinical validation of these results is needed.
Keywords: Meropenem, Continuous renal replacement therapy, Asian critically ill patients, Monte Carlo simulations, Drug dosing.
Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy
Faculty of Pharmacy, Siam University, Bangkok, Thailand
- Thromboprophylaxis in Multiple Myeloma Patients Receiving Immunomodulatory Drugs
- The Perspective of Stakeholders towards the Problems and Solutions of Health Products Available Through Social Commerce in Thailand
- Prognostic Value of Serum Procalcitonin level for the Diagnosis of Bacterial Infections in Critically-ill Patients
- Formulation and in-vitro evaluation of fast dissolving tablets using superdisintegrant blend with effervescent materia
- Doripenem dosing regimens in Asian critically ill patients with continuous real replacement therapy
- Doripenem dosing in Asian critically ill patients with continuous renal replacement therapy
- Design and characterisation of electrospun shellac-polyvinylpyrrolidone blended micro/nanofibres loaded with monolaurin for application in wound healing